Levorphanol Write-Down Dents Zydus in Q2 But Saroglitazar Expectations Build
Moraiya Unit Reinspection Expected In June
Executive Summary
As returns from levorphanol fall on the back of increased competition, Zydus Cadila writes down investment by $37.5m causing Q2 profits to slump 74%. Post successful Phase II trials in the US for NASH and NAFLD indications, its hopes are now pinned on saroglitazar magnesium.
You may also be interested in...
India 2019 – R&D Highs, Compliance Woes And Other Lows
2019 saw Indian companies advance innovation efforts and build and expand their specialty portfolios and biosimilars businesses. But manufacturing compliance issues weighed down several firms while on another front charges against the Singh brothers of Ranbaxy escalated.
India 2019 – R&D Highs, Compliance Woes And Other Lows
2019 saw Indian companies advance innovation efforts and build and expand their specialty portfolios and biosimilars businesses. But manufacturing compliance issues weighed down several firms while on another front charges against the Singh brothers of Ranbaxy escalated.
Cadila Healthcare Merges Four Subsidiaries
India’s Cadila Healthcare, which has been suffering on the earnings front, is amalgamating four subsidiaries under its roof to reduce overheads from managing separate entities and avoid duplication of efforts after posting weak second-quarter earnings.
Need a specific report? 1000+ reports available
Buy Reports
